Albert Jean Robichaud

This inventor holds 111 USPTO granted patents and 70 published patent applications, plus 14 CIPO patents and 45 EPO patents, primarily in Neuroactive Steroids (CPC class C07J43-003). Top assignees: Sage Therapeutics, Inc., Wyeth, Bristol-Myers Squibb Pharma Company. Active years: 2003-2026.

USPTO Granted Patents = 111 (Patent Applications = 70)

% Patents Active = 83.8

CIPO Patents = 14 (Patent Applications = 14)

EPO Patents = 45 (Patent Applications = 67)

Average Co-Inventor Count = 4.4

ph-index = 23

Forward Citations = 2,330(Granted Patents)

Forward Citations (Not Self Cited) = 1,607(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Ladenberg, PA (US) (2004)
Landenberg, PA (US) (2003 - 2007)
Ringoes, NJ (US) (2005 - 2019)
Cambridge, MA (US) (2018 - 2024)
Boston, MA (US) (2020 - 2024)

Company Filing History:

77 out of 99

Sage Therapeutics, Inc.

Bristol-Myers Squibb Pharma Company

patents

4. 5 out of 3,736

Bristol-Myers Squibb Compnay

patents

5. 3 out of 1,376

Washington University

patents

6. 1 out of 1

Sage Therpeutics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Neuroactive Steroids

Oxysterols

CNS Disorders

Compositions

Pharmaceuticals

Steroid Treatments

C7 Substituted

19-nor Steroids

C12 Substituted

C16 Substituted

C21 Compounds

C3,3-Disubstituted

111 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655175 - C17, C20, and C21 substituted neuroactive steroids and their methods of use (2026-06-16),

2. 12617814 - Neuroactive steroids and methods of use thereof (2026-05-05),

3. 12540157 - Oxysterols and methods of use thereof (2026-02-03),

4. 12534495 - Compositions and methods for treating CNS disorders (2026-01-27),

5. 12473327 - Neuroactive steroids, compositions and uses thereof (2025-11-18),

6. 12448409 - Oxysterols and methods of use thereof (2025-10-21),

7. 12421275 - Compositions and methods for treating CNS disorders (2025-09-23),

8. 12331070 - C7 substituted oxysterols and methods of use thereof (2025-06-17),

9. 12268697 - Oxysterols and methods of use thereof (2025-04-08),

10. 12201640 - 19-nor C3,3-disubstituted C21-n-pyrazolyl steroids and methods of use thereof (2025-01-21),

11. 12180248 - Compositions and methods for treating CNS disorders (2024-12-31),

12. 12180247 - Oxysterols and methods of use thereof (2024-12-31),

13. 12129276 - Oxysterols and methods of use thereof (2024-10-29),

14. 12129275 - Neuroactive steroids, compositions, and uses thereof (2024-10-29),

15. 12071453 - Neuroactive steroids, compositions, and uses thereof (2024-08-27),

Title: The Innovative Journey of Inventor Albert Jean Robichaud

Introduction:

Albert Jean Robichaud, a prolific inventor based in Ringoes, NJ, has left a significant mark in the field of CNS disorder treatment with his groundbreaking patents.

Latest Patents:

Albert Jean Robichaud's latest patents include compositions and methods for treating CNS disorders. These patents focus on neuroactive steroids and C7 substituted oxysterols, which have shown promise as GABA modulators and for the prevention and treatment of various conditions.

Career Highlights:

With an impressive portfolio of 92 patents, Albert Jean Robichaud has demonstrated his expertise and commitment to advancing pharmaceutical innovations. He has made significant contributions to companies such as Sage Therapeutics, Inc. and Wyeth, where his innovative research has paved the way for novel treatment methods.

Collaborations:

Throughout his career, Albert Jean Robichaud has collaborated with esteemed professionals in the field, including Francesco Gerald Salituro and Gabriel Martinez Botella. These collaborations have enriched his research endeavors and led to impactful developments in the field of CNS disorder treatment.

Conclusion:

Albert Jean Robichaud's relentless pursuit of innovation and dedication to improving healthcare outcomes through his patented inventions exemplify his status as a visionary inventor. His contributions continue to inspire advancements in the pharmaceutical industry, shaping the future of CNS disorder treatment.